Investor Relations

Latest Financial Results

FY 2023

Fiscal Year Ended Dec 31, 2023

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Latest Presentation

Investor Presentation

Company Overview

SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas.

Stock Snapshot

IR Contacts

Company

SCYNEXIS, Inc.
1 Evertrust Plaza
13th Floor
Jersey City, NJ 07302
T: (201) 884-5485
info@scynexis.com

Investor Relations

LifeSci Advisors
Irina Koffler
T: 646-970-4681
ikoffler@lifesciadvisors.com

Media

Ivor Macleod
Chief Financial Officer
Ivor.macleod@scynexis.com

Transfer Agent

American Stock Transfer & Trust Company, LLC
10150 Mallard Creek Road
Suite 307
Charlotte, NC 28262
T: 800-937-5449

Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.